Özdemir, ÖnerEngin, Muhammet Mesut Nezir2023-04-102023-04-1020211307-671Xhttp://doi.org/10.18678/dtfd.856165https://search.trdizin.gov.tr/yayin/detay/421855https://hdl.handle.net/20.500.12684/11415December 2019. SARS-CoV-2 infection in human was named as coronavirus disease 2019(COVID-19). It has now infected more than 69 million people worldwide, becoming anepidemic responsible for more than 1,5 million deaths until 10th of December 2020. Theepidemic still continues. This epidemic is the third epidemic caused by coronaviruses in the21st century and may be the most important infectious disease representing a major publichealth threat to the whole world. Treatments against COVID-19 are constantly updated in theliterature, based on evidence. Unfortunately, there is no definitive cure for COVID-19, and anumber of drugs for use in severe cases of COVID-19 are now being studied in a number ofnonrandomized or randomized trials. These include chloroquine, steroids, anti-inflammatory,and antiviral agents. Immunological treatments such as convalescent plasma, intravenousimmunoglobulin, monoclonal antibodies (tocilizumab, eculizumab, itolizumab etc.), andanakinra treatments are tried in COVID-19 disease. Results from some trials look promising.Quite a few reports have also stood published so far on the use of immunological treatmentsfor COVID-19 cases. In this review, we will discuss the key immunological treatments, mostlymentioned in the current literature, used in COVID-19 patients in detail.en10.18678/dtfd.856165info:eu-repo/semantics/openAccessArticle23119421855